BIIB

#493
Biogen Inc. Common Stock
180.54 USD
+0.88%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
180.54
180.54
年范围
114.66
202.41
日变化
+0.88%
每月变动
-2.27%
6个月变化
+27.05%
年变化
+56.73%
前一天收盘价
178.96
开盘价
180.54
买价
卖价
最低价
180.54
High
180.54
交易量
158
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 26.5 B
  • Employee 7 500
  • Founded 1978
  • CEO Chris Viehbacher
  • Website www.biogen.com
  • Headquarter Delaware, United States
  • FIGI BBG000C17X76
  • Industry 药品制造—常规
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
20.02
市销率
2.62

Biogen Inc

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

新闻